Related Experiment Video
Updated: Dec 18, 2025
Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
Update on GNA Alterations in Cancer: Implications for Uveal Melanoma Treatment
Lionel Larribère1,2, Jochen Utikal1,2
1Skin Cancer Unit, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Abstract:
Tumorigenesis is correlated with abnormal expression and activity of G protein-coupled receptors (GPCRs) and associated G proteins. Oncogenic mutations in both GPCRs and G proteins (GNAS, GNAQ or GNA11) encoding genes have been identified in a significant number of tumors. Interestingly, uveal melanoma driver mutations in GNAQ/GNA11 were identified for a decade, but their discovery did not lead to mutation-specific drug development, unlike it the case for BRAF mutations in cutaneous melanoma which saw enormous success. Moreover, new immunotherapies strategies such as immune checkpoint inhibitors have given underwhelming results. In this review, we summarize the current knowledge on cancer-associated alterations of GPCRs and G proteins and we focus on the case of uveal melanoma. Finally, we discuss the possibilities that this signaling might represent in regard to novel drug development for cancer prevention and treatment.
Insights
Tumorigenesis involves altered G protein-coupled receptors (GPCRs) and G proteins. Uveal melanoma research highlights GNAQ/GNA11 mutations, yet targeted therapies and immunotherapies show limited success, necessitating new drug development strategies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Abnormal expression and activity of G protein-coupled receptors (GPCRs) and G proteins are linked to tumorigenesis.
- Oncogenic mutations in genes encoding GPCRs and G proteins (GNAS, GNAQ, GNA11) are found in numerous cancers.
- Uveal melanoma is driven by GNAQ/GNA11 mutations, but this has not yet translated into mutation-specific drug development.
Purpose of the Study:
- To review current knowledge on cancer-associated alterations in GPCRs and G proteins.
- To focus on the specific case of uveal melanoma and its genetic drivers.
- To explore the potential of GPCR-G protein signaling for novel cancer therapeutic strategies.
Main Methods:
- Literature review of studies on GPCRs, G proteins, and cancer.
- Analysis of genetic alterations in uveal melanoma, particularly GNAQ/GNA11 mutations.
- Discussion of signaling pathways and therapeutic implications.
Main Results:
- GPCRs and G proteins are frequently dysregulated in cancer.
- GNAQ/GNA11 mutations are key drivers in uveal melanoma.
- Current targeted therapies and immunotherapies have shown limited efficacy in uveal melanoma.
Conclusions:
- GPCR-G protein signaling represents a promising avenue for developing novel cancer prevention and treatment strategies.
- Further research into these pathways could lead to effective therapies for challenging cancers like uveal melanoma.
- Targeting GPCR-G protein signaling may overcome limitations of current treatment modalities.
